Stéphane Budel, founding partner at DeciBio, joins the Talking Precision Medicine Podcast to explore the future of the field. He unpacks how liquid biopsy, multi-omics, and AI are opening new doors for personalized care, why the diagnostics business model is holding innovation back, and what it will take to make complex tech usable for clinicians and patients alike.<a href="https://www.genialis.com/2025/05/19/precision-medicine-is-our-future-and-our-fate-tpm-podcast-46/" target="_blank" rel="ugc noopener noreferrer">⁠TPM E46 highlights &gt;⁠⁠⁠⁠⁠⁠⁠⁠</a>Episode 46 links:<ul><li><a href="https://www.decibio.com" target="_blank" rel="ugc noopener noreferrer">DeciBio</a></li></ul><ul><li><a href="https://www.linkedin.com/in/budel/" target="_blank" rel="ugc noopener noreferrer">Stephane Budel on LinkedIn</a></li></ul><ul><a href="https://www.decibio.com/insights/inflection-points-of-artificial-intelligence-in-drug-development-white-paper" target="_blank" rel="ugc noopener noreferrer">DeciBio’s White Paper on AI in Drug Development (with contributions from Rafael Rosengarten)</a></ul>

Tom Neyarapally, Archetype Therapeutics | A new paradigm for generative AI drug discovery: more accurate shots on a much wider goal | TPM podcast #47

Welcome to the Talking Precision Medicine podcast. In this series, we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.